Investigations of Juvenile Neuronal Ceroid Lipofuscinosis

Status Recruiting

Clinical Trial Summary

Background: CLN3, or Batten disease, is a genetic disorder. This deadly disease leads to decline of brain and nervous system functions. Symptoms of CLN3 typically occur between 4 and 7 years of age. They include changes in how a person sees, thinks, and moves. CLN3 can also cause seizures. No effective treatments for the disease are yet known. There is limited testing of potential therapies. Researchers want to study CLN3 more so they can improve future therapies. Objective: To identify clinical or biochemical markers that can be used as therapeutic outcome measures for CLN3. Eligibility: People with CLN3. It must be based on Two CLN3 mutations OR One CLN3 mutation AND findings seen with a powerful microscope Family members of a person with CLN3. Design: Participants will have already been referred to NIH for CLN3 evaluation. If participants agree to do the study, they will: 1. give spinal fluid, blood, urine, and skin samples. They may provide other samples if they were already collected. These may include cells, surgical specimens, and DNA. 2. will be seen by multiple healthcare specialists. Participants may provide medical records or photos. Participants will sign a release of medical records form.P Researchers may send samples or clinical data to other investigators. For research testing, the samples will not include the participant s name. For a test in a clinical lab, researchers will include the participant s name. These results will become part of the clinical record at NIH.

Clinical Trial Description

Study Description: The purpose of this protocol is to obtain both baseline and rate of progression data on clinical and biochemical markers that may later be used as an outcome measure in a clinical trial, and to establish a biorepository of samples from CLN3 participants. For comparisons, focused clinical data and relevant evaluations and biospecimens will also be collected from individuals with Neuronal Ceroids Lipofuscinosis (NCL) of other types and from family members of all affected individuals. Objectives: Primary Objective: 1. Identify clinical or biochemical markers that can be used as therapeutic outcome measures for CLN3. 2. Evaluate clinical aspects of CLN3 to provide tools for future therapeutic trials. Secondary Objectives: Establish a biorepository of samples from well-characterized individuals with CLN3, and family members of CLN3 individuals, for future research related to CLN3. Endpoints: Primary Endpoint: 1. Blood, urine, or CSF biomarkers. 2. Proportion of participants who achieve a clinically valid and interpretable score on administered measures. 3. Scores obtained for each administered measure. Secondary Endpoints: Tolerability and feasibility of each measure of the clinical battery of assessments based on clinician observation. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03307304
Study type	Observational
Source	National Institutes of Health Clinical Center (CC)
Contact	An N Dang Do, M.D.
Phone	(301) 496-8849
Email	an.dangdo@nih.gov
Status	Recruiting
Phase
Start date	November 27, 2017
Completion date	December 31, 2050

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT02254863` - UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like Cells	Phase 1
Completed	`NCT01907087` - A Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Intracerebroventricular BMN 190 in Patients With Late-Infantile Neuronal Ceroid Lipofuscinosis (CLN2) Disease	Phase 1/Phase 2
Active, not recruiting	`NCT03770572` - Gene Therapy for Children With CLN3 Batten Disease	Phase 1/Phase 2
Recruiting	`NCT06203106` - NYSCF Scientific Discovery Biobank
Completed	`NCT00151268` - Genotype - Phenotype Correlations of LINCL	N/A
Recruiting	`NCT02435940` - Inherited Retinal Degenerative Disease Registry
Completed	`NCT01035424` - Genotype-Phenotype Correlations of Late Infantile Neuronal Ceroid Lipofuscinosis
Completed	`NCT00151216` - Safety Study of a Gene Transfer Vector for Children With Late Infantile Neuronal Ceroid Lipofuscinosis	Phase 1
Active, not recruiting	`NCT04273243` - Long-Term Follow Up of CLN6 Batten Disease Subjects Following Gene Transfer
Recruiting	`NCT03285425` - Natural History of Neuronal Ceroid Lipofuscinosis, Batten's CLN6 Diseae
Completed	`NCT00176904` - Stem Cell Transplant for Inborn Errors of Metabolism	Phase 2/Phase 3
Recruiting	`NCT03333200` - Longitudinal Study of Neurodegenerative Disorders
Completed	`NCT02678689` - A Safety, Tolerability, and Efficacy Study of Intracerebroventricular BMN 190 in Pediatric Patients < 18 Years of Age With CLN2 Disease	Phase 2
Completed	`NCT02485899` - An Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 190 in Patients With CLN2 Disease	Phase 1/Phase 2
Active, not recruiting	`NCT05174039` - An Open-label Safety, Pharmacokinetic, and Efficacy Study of Miglustat for the Treatment of CLN3 Disease	Phase 1/Phase 2
Terminated	`NCT01698229` - Collection of Cerebrospinal Fluid in Healthy Children	N/A
Enrolling by invitation	`NCT03862274` - Examining Developmental Outcomes of Children Diagnosed With CLN2 Disease
Recruiting	`NCT01873924` - Clinical and Neuropsychological Investigations in Batten Disease
Completed	`NCT01161576` - Safety Study of a Gene Transfer Vector (Rh.10) for Children With Late Infantile Neuronal Ceroid Lipofuscinosis (LINCL)	Phase 1
Recruiting	`NCT04613089` - Natural History and Longitudinal Clinical Assessments in NCL / Batten Disease, the International DEM-CHILD Database